Investor Presentaiton slide image

Investor Presentaiton

Investor presentation ADA 2019 Slide 7 Key inclusion criteria defining established CVD differ between GLP-1 CVOTs but trial populations are more comparable with aligned definitions Key inclusion criteria defining established cardiovascular disease across selected CVOTS Established CVD Without established CVD REWIND 21 prior CVD MI Ischaemic stroke Revascularisation.* Hospitalisation for unstable angina Myocardial ischaemia PCI Age 50 to 54 years, with 21 prior CVD Age 55 to 60 years, the above, or evidence of other vascular or renal disease Age ≥60 years, the above, or 2 CV risk factors LEADER/SUSTAIN 63 21 of the following: • CVD CeVD PVD Chronic HF (NYHA class II or III) Chronic kidney disease of stage 3 or higher LEADER: age ≥50 years with 21 prior CVD SUSTAIN 6: age ≥50 years with clinical evidence of CVD LEADER: age ≥60 years with 21 CV risk factor SUSTAIN 6: age ≥60 years with subclinical evidence of CVD Trial population based on previous MI/stroke vs CV risk factors MI/Stroke CV risk factors 22%¹ 40% 41% 78% 60% 59% REWIND n=9,901 LEADER n=9,340 Mean follow up: 5.4 years Mean follow up: 3.8 years SUSTAIN 6 n=3,297 Mean follow up: 2.1 years *Coronary: carotid or peripheral; CeVD: cerebrovascular disease; CV; cardiovascular; CVD: cardiovascular disease; CVOT: cardiovascular outcomes trial; HF: heart failure; MI: myocardial infarction; NYHA: New York Heart Association; PCI: percutaneous coronary intervention; PVD: peripheral vascular disease 1844; 5. 1. Gerstein HC et al. Diabetes Obes Metab 2017, Based on 1. Gerstein, HC et al. Diabetes Obes Metab 2017; doi:10.1111/dom. 13028; 2. Marso SP et al. N Engl J Med 2016;375 311-322; 3. Marso SP et al. N Engl J Med 2016; Ischaemic stroke (5.3%) and Prior MI (16.2%);
View entire presentation